隐匿性癌症相关首次静脉血栓栓塞与静脉血栓栓塞复发风险增加相关
基于1994-2012年特罗姆瑟1-6期调查中733例首次静脉血栓栓塞(VTE)患者,比较隐匿癌、显性癌与非癌症患者的VTE复发风险。隐匿癌组1年累积复发率为38.6%,显性癌组为15.5%,非癌症组为3.8%;隐匿癌组1年复发风险为非癌症组的12倍(HR 12.4,95%CI 5.9-26.3),显性癌组为4倍(HR 4.3,95%CI 2.0-9.2)。作者认为隐匿癌患者复发风险增高主要归因于其晚期癌症。
要点
- 隐匿癌相关首次VTE的1年累积复发率为38.6%,高于显性癌的15.5%和非癌症的3.8%。
- 隐匿癌组1年复发风险为非癌症组的12倍(HR 12.4,95%CI 5.9-26.3)。
- 隐匿癌组69%的复发发生在癌症诊断前或诊断后不久,故与治疗无关。
核心结论
- 作者认为,隐匿癌患者VTE复发风险增高主要归因于这些患者的晚期癌症。
研究设计与样本
- 纳入1994-2012年特罗姆瑟第1至第6期调查中发生首次VTE的参与者,共733例患者,其中显性癌110例、隐匿癌40例。
- 隐匿癌定义为VTE后1年内诊断的癌症,显性癌定义为VTE前2年内诊断的癌症。
- 中位随访3.2年,期间发生95例VTE复发事件。
主要发现
- VTE复发1年累积发生率:隐匿癌组38.6%,显性癌组15.5%,非癌症组3.8%。
- 1年复发风险:隐匿癌组为非癌症组的12倍(HR 12.4,95%CI 5.9-26.3),显性癌组为非癌症组的4倍(HR 4.3,95%CI 2.0-9.2)。
- 与VTE复发相关的隐匿癌通常位于促血栓部位(即肺和胃肠道),并呈晚期表现。
- 隐匿癌组69%的复发发生在癌症诊断前或诊断后不久,因此与治疗无关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Essentials Recurrence risk after an occult cancer-related incident venous thromboembolism (VTE) is unknown. We compared the risk of VTE recurrence in occult-, overt- and non-cancer related first VTE. Patients with occult-cancer related first VTE had the highest risk of VTE recurrence. The high recurrence risk in occult cancer is likely due to the advanced cancers. SUMMARY: Background Although venous thromboembolism (VTE) is associated with a high recurrence rate, the absolute recurrence rates for cancer-related VTE, particularly occult cancer, are not well known. Objectives To investigate the risk of VTE recurrence in patients with occult and overt cancer-related VTE. Methods Incident VTE events among participants of the first to sixth Tromsø surveys occurring in the period 1994-2012 were included. Occult cancer was defined as cancer diagnosed within a year following a VTE, and overt cancer was defined as cancer diagnosed within the 2 years before a VTE. Results Among 733 patients with incident VTE, 110 had overt cancer and 40 had occult cancer. There were 95 recurrent VTE events during a median of 3.2 years of follow-up. The 1-year cumulative incidence of VTE recurrence was 38.6% in subjects with occult cancer, 15.5% in subjects with overt cancer, and 3.8% in non-cancer subjects. The 1-year risk of recurrence was 12-fold (hazard ratio [HR] 12.4, 95% confidence interval [CI] 5.9-26.3) higher in subjects with occult cancer and four-fold (HR 4.3, 95% CI 2.0-9.2) higher in subjects with overt cancer than in non-cancer subjects. The occult cancers associated with VTE recurrence were typically located at prothrombotic sites (i.e. lung and gastrointestinal) and presented at advanced stages. The majority (69%) of recurrences in subjects with occult cancer occurred before or shortly after cancer diagnosis, and were therefore not treatment-related. Conclusion Our findings suggest that the increased risk of recurrence in patients with occult cancer is mainly attributable to the advanced cancers in these patients.
引用
- Gran OV, Braekkan SK, Paulsen B, et al. Occult cancer-related first venous thromboembolism is associated with an increased risk of recurrent venous thromboembolism. J Thromb Haemost. 2017. PMID: 28440069. doi:10.1111/jth.13714
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。